Previous 10 | Next 10 |
Today's stock bear market has only just begun. No relief in sight. Elevate your stock investment strategy to find opportunities that remain abundant within the broader market. For further details see: We've Only Just Begun
As the MOMO, YOLO, and BTFD days sink deeper into the past, we remind investors to focus on fundamentals. Johnson & Johnson’s scale and diversified business greatly reduce the risk generally involved when investing in pharmaceutical stocks heavily dependent on a handful of ...
With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...
Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...
During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...
With April 2022 trading in the books, the U.S. large pharmaceutical sector had a fairly mediocre month, though it still performed better than the S&P 500 Index. The iShares U.S. Pharmaceuticals ETF (IHE), which tracks the Dow Jones U.S. Select Pharmaceuticals Index, finished the month ...
Typically, we look at net new highs as a way to confirm moves in the broader market. At the high last Wednesday, over 90% of S&P 500’s new highs came from defensive sectors. In other words, defensives have been a notable pocket of strength recently. For further de...
Stock markets fell in the first quarter as Russia’s invasion of Ukraine destabilized the growth outlook, amplified concerns about rising interest rates and unleashed geopolitical risks. While the conflict has created many uncertainties, we believe the impact of persistent infla...
The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities. Significant portfolio transitions centered around the separation of consumer health care businesses are underway among large pharmaceutical companie...
iShares U.S. Pharmaceuticals ETF (IHE) - $0.7935. 30-Day SEC Yield of 1.73% as of Feb. 28. Payable Mar 30; for shareholders of record Mar 25; ex-div Mar 24. For further details see: iShares U.S. Pharmaceuticals ETF declares quarterly distribution of $0.7935
News, Short Squeeze, Breakout and More Instantly...
iShares U.S. Pharmaceutical Company Name:
IHE Stock Symbol:
NYSE Market:
2024-07-12 08:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-22 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-31 20:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...